Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation

Transplantation

Volumn 48, Issue 3, 1989, Pages 524-526

  Toussaint, Charles ^a   De Pauw, Luc ^a   Vereerstraeten, Pierre ^a   Kinnaert, Paul ^a   Abramowicz, Daniel ^a   Goldman, Michel ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYDROCORTISONE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OKT 3;

CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CYCLOSPORINS; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; TIME FACTORS;

EID: 0024417821     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-198909000-00036     Document Type: Article

References (11)

1. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
2. Thistlethwhaite JR Jr, Haag BW, Gaber AO, et al. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine. Transplant Proc 1987; 19: 1901.
3. Vigeral P, Chkoff N, Chatenoud L, et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients: utilization of OKT3 as the sole immunosuppressive agent. Transplantation 1986; 41: 730.
4. Norman DJ, Shield CF, Barry J, et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis 1988; 11: 107.
5. Ackerman JR, LeFor WM, Kahana L, et al. Prophylactic use of OKT3 in renal transplantation: part of a prospective randomized multicenter trial. Transplant Proc 1988; 20: 242.
6. Shield CF, Hughes JD, Lemon JA. Prophylactic OKT3 and cadaveric renal transplantation at a single center. Clin Transplant 1988; 2: 190.
7. Wagner K, Albrecht S, Neumayer HH. Prevention of delayed graft function in cadaver kidney transplantation by a calcium antagonist: preliminary results of two prospective randomized trials. Transplant Proc 1986; 18: 510.
8. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
9. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470.
10. Christiansen NP, Skubitz KM, Nath K, et al. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin 2. Am J Med 1988; 84: 1072.
11. Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319: 1397.